Emergent BioSolutions Shareholder Derivative Litigation
In re Emergent Biosolutions Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ (Del. Ch.)
Lieff Cabraser serves as Co-Lead Counsel in this shareholder derivative action against certain officers and directors of Emergent BioSolutions, a vaccine manufacturer, for breach of their fiduciary duties to the company by failing to implement necessary controls and procedures to ensure that the company manufactured safe and effective vaccines. In 2025, the case settled for $15 million and extensive corporate governance reforms.
